MR-guided ultrasound developer Insightec said the U.S. Food and Drug Administration (FDA) has approved the use of its Exablate Neuro neurosurgery technology for treating patients with Parkinson's disease.
Exablate Neuro uses MR-guided focused ultrasound to ablate small targets in the brain without incisions. The device had already received FDA approval for treating medication-refractory essential tremor in 2016, and in 2018 for tremor-dominant Parkinson's disease.
The new approval applies to Parkinson's disease patients who are suffering from mobility, rigidity, or dyskinesia symptoms, according to the company.
